Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer

被引：36

作者：

Islam, Rajibul ^{[1
]}

Lam, Kok Wai ^{[1
]}

机构：

[1] Univ Kebangsaan Malaysia, Fac Pharm, Drugs & Herbal Res Ctr, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2020年 / 207卷

关键词：

Triple-negative breast cancer; Small molecule agent; Targeted therapy; Immunotherapy; Combination therapy; HISTONE DEACETYLASE INHIBITOR; IN-VIVO ACTIVITY; TUMOR-GROWTH; ANTIPROLIFERATIVE ACTIVITY; PROTEASOME INHIBITOR; ANTITUMOR-ACTIVITY; DOWN-REGULATION; CDK INHIBITION; MUTANT P53; STEM-CELLS;

D O I：

10.1016/j.ejmech.2020.112812

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Triple-negative breast cancer (TNBC) is the most aggressive type of cancer, with a high risk of death on recurrence. To date, there is a lack of approved targeted agents for the treatment of the disease. Patients with TNBC continue to depend on surgery, chemotherapy, and radiotherapy, all of which have a wide side effect profile. In the present review, we highlight the current progress and exciting developments in the small-molecule targeted therapy for the treatment of TNBC. Finally, we also discuss the prospect of combining targeted therapy and immunotherapy for the effective treatment of TNBC. (C) 2020 Elsevier Masson SAS. All rights reserved.

引用

页数：21

共 179 条

[91]

Lucantoni Federico, 2018, Oncotarget, V9, P26046, DOI 10.18632/oncotarget.25433

[92]

Machl A, 2016, AM J CANCER RES, V6, P806

[93] Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer [J].

Maji, Santanu ;

Panda, Sanjay ;

Samal, Sabindra K. ;

Shriwas, Omprakash ;

Rath, Rachna ;

Pellecchia, Maurizio ;

Emdad, Luni ;

Das, Swadesh K. ;

Fisher, Paul B. ;

Dash, Rupesh .

ADVANCES IN CANCER RESEARCH, VOL 137, 2018, 137 :37-75

[94] HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes [J].

Mbofung, Rina M. ;

McKenzie, Jodi A. ;

Malu, Shruti ;

Zhang, Min ;

Peng, Weiyi ;

Liu, Chengwen ;

Kuiatse, Isere ;

Tieu, Trang ;

Williams, Leila ;

Devi, Seram ;

Ashkin, Emily ;

Xu, Chunyu ;

Huang, Lu ;

Zhang, Minying ;

Talukder, Amjad H. ;

Tripathi, Satyendra C. ;

Khong, Hiep ;

Satani, Nikunj ;

Muller, Florian L. ;

Roszik, Jason ;

Heffernan, Timothy ;

Allison, James P. ;

Lizee, Gregory ;

Hanash, Sam M. ;

Proia, David ;

Amaria, Rodabe ;

Davis, R. Eric ;

Hwu, Patrick .

NATURE COMMUNICATIONS, 2017, 8

[95] Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer [J].

Merino, Delphine ;

Whittle, James R. ;

Vaillant, Francois ;

Serrano, Antonin ;

Gong, Jia-Nan ;

Giner, Goknur ;

Maragno, Ana Leticia ;

Chanrion, Maia ;

Schneider, Emilie ;

Pal, Bhupinder ;

Li, Xiang ;

Dewson, Grant ;

Grasel, Julius ;

Liu, Kevin ;

Lalaoui, Najoua ;

Segal, David ;

Herold, Marco J. ;

Huang, David C. S. ;

Smyth, Gordon K. ;

Geneste, Olivier ;

Lessene, Guillaume ;

Visvader, Jane E. ;

Lindeman, Geoffrey J. .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (401)

[96] Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells [J].

Min, Ahrum ;

Im, Seock-Ah ;

Kim, Debora Keunyoung ;

Song, Sang-Hyun ;

Kim, Hee-Jun ;

Lee, Kyung-Hun ;

Kim, Tae-Yong ;

Han, Sae-Won ;

Oh, Do-Youn ;

Kim, Tae-You ;

O'Connor, Mark J. ;

Bang, Yung-Jue .

BREAST CANCER RESEARCH, 2015, 17

[97] Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer [J].

Morales, Paula ;

Blasco-Benito, Sandra ;

Andradas, Clara ;

Gomez-Canas, Maria ;

Maria Flores, Juana ;

Goya, Pilar ;

Fernandez-Ruiz, Javier ;

Sanchez, Cristina ;

Jagerovic, Nadine .

JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (05) :2256-2264

[98] FOXP3 and Its Cofactors as Targets of Immunotherapies [J].

Nagai, Yasuhiro ;

Lam, Lian ;

Greene, Mark I. ;

Zhang, Hongtao .

ENGINEERING, 2019, 5 (01) :115-121

[99] Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells [J].

Nair, Varun Sasidharan ;

Toor, Salman M. ;

Ali, Bassam R. ;

Elkord, Eyad .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (06) :547-557

[100] Novel sesquiterpene lactone analogues as potent anti-breast cancer agents [J].

Nakagawa-Goto, Kyoko ;

Chen, Jo-Yu ;

Cheng, Yu-Ting ;

Lee, Wai-Leng ;

Takeya, Munehisa ;

Saito, Yohei ;

Lee, Kuo-Hsiung ;

Shyur, Lie-Fen .

MOLECULAR ONCOLOGY, 2016, 10 (06) :921-937

← 5 6 7 8 9 10 11 12 13 14 →